content: UNITED STATES
                         SECURITIES AND EXCHANGE COMMISSION
                               WASHINGTON, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
  
  
           Date of Report (Date of earliest event reported): April 8, 2005
  
                                 HENRY SCHEIN, INC.
               (Exact name of registrant as specified in its charter)
  
  
          Delaware                     0-27078                 11-3136595
  --------------------------------------------------------------------------------
  (State or other jurisdiction of (Commission Number) (IRS Employer Identification
         incorporation)                                           No.)
  
  
                 135 Duryea Road Melville, New York                  11747
  --------------------------------------------------------------------------------
              (Address of principal executive offices)             (Zip Code)
  
  Registrant's telephone number, including area code:  (631) 843-5500
                                                     -----------------------------
  
  --------------------------------------------------------------------------------
           (Former name or former address, if changed since last report.)
  
  Check the appropriate box below if the Form 8-K filing is intended to
  simultaneously satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
  [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)
  
  [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)
  
  [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
      Act (17 CFR 240.14d-2(b))
  
  [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
      Act (17 CFR 240.13e-4(c))
  
  
  <PAGE>
  
  
  ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
  APPOINTMENT OF PRINCIPAL OFFICERS
  
  On April 8, 2005, the Company's Board of Directors authorized an increase in the
  number of directors, which constitute the entire Board of Directors, from
  fourteen to fifteen and appointed Paul Brons as a new director, effective
  immediately, to fill the vacancy created. Mr. Brons' term will expire at the
  Company's annual meeting of stockholders to be held on May 24, 2005. Attached
  hereto and incorporated herein by reference as Exhibit 99.1 is a copy of the
  Company's press release announcing Mr. Brons' appointment to the Company's Board
  of Directors.
  
  ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
  
  (c) Exhibit 99.1 - Press Release dated April 11, 2005.
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  Pursuant to the requirements of the Securities and Exchange Act of 1934, the
  Registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                            HENRY SCHEIN, INC.
  
  Date: April 11, 2005                       By:  /s/ Michael S. Ettinger
                                                ------------------------------
                                                Name: Michael S. Ettinger
                                                Title: Vice President and General
                                                       Counsel
  
  
  <PAGE>
  
  
                                                             EXHIBIT 99.1
  
                           [LOGO OMITTED] HENRY SCHEIN(R)
                                N E W S R E L E A S E
           Henry Schein, Inc. - 135 Duryea Road, Melville, New York 11747
                                          FOR:     HENRY SCHEIN, INC.
                                          CONTACT: STEVEN PALADINO
                                                   EXECUTIVE VICE PRESIDENT &
                                                   CHIEF FINANCIAL OFFICER
                                                   (631) 843-5500
                                                   STEVEN.PALADINO@HENRYSCHEIN.COM
  
                                                   SUSAN VASSALLO
                                                   DIRECTOR,
                                                   CORPORATE COMMUNICATIONS
                                                   (631) 843-5562
                                                   SUSAN.VASSALLO@HENRYSCHEIN.COM
  
               HENRY SCHEIN APPOINTS PAUL BRONS TO BOARD OF DIRECTORS
  
               FORMER MEMBER OF AKZO NOBEL BOARD OF MANAGEMENT BRINGS
                     INTERNATIONAL AND PHARMACEUTICAL EXPERIENCE
  
  MELVILLE, N.Y., APRIL 11, 2005 - Henry Schein, Inc. (NASDAQ: HSIC), the largest
  distributor of healthcare products and services to office-based practitioners in
  the combined North American and European markets, today announced the
  appointment of Paul Brons to the Henry Schein Board of Directors. Mr. Brons is a
  former member of the Board of Management of Akzo Nobel NV, a leading
  manufacturer of diversified pharmaceutical, coatings and chemical products in
  over 75 countries.
  
      As a member of the Akzo Nobel Board of Management for eight years, Mr. Brons
  led all of the company's pharmaceutical business units, including human and
  veterinary pharmaceuticals, OTCs, generics, diagnostics and pharmaceutical
  active ingredients. In addition to his pharma responsibilities, Mr. Brons also
  supervised Akzo Nobel's corporate purchasing, information technology and
  international business development; as well as the company's activities in China
  and Latin America. Prior to his tenure on the Board of Management, Mr. Brons
  served as President of Organon International BV, one of Akzo Nobel's pharma
  business units, for nine years, the culmination of a 29-year career with that
  company, which included several posts abroad.
  
      "We are delighted to have a person of Paul's caliber join the Henry Schein
  Board of Directors," said Stanley M. Bergman, Chairman, Chief Executive Officer
  and President of Henry Schein. "Paul's wide-ranging international business
  experience and his expertise in pharmaceuticals have earned him a well-deserved
  reputation as one of Europe's premier pharmaceutical industry leaders. Our Board
  of Directors and management team look forward to the valuable contributions Paul
  will make to our company as we continue to expand internationally and add to our
  portfolio of pharmaceuticals, vaccines and other injectables."
  
                                      - more -
  
  
  <PAGE>
  
  
  Page 2
  
      While at Akzo Nobel, Mr. Brons contributed to the strengthening of the
  European Federation of Pharmaceutical Industry Associations (EFPIA), first as a
  member of its Strategic Advisory Committee, then as a member of their Board, and
  Chairman of EFPIA's EU Enlargement Committee. He was for many years actively
  involved in a worldwide policy group of CEOs from international R&D-based
  pharmaceutical companies, which sought to foster cooperation with governmental
  and non-governmental organizations. He also served as the European
  representative for the pharmaceutical industry at the Trans-Atlantic Business
  Dialogue, examining such issues as patent extension and AIDS in Africa.
  
      Since retiring from the Akzo Nobel Board of Management in 2002, Mr. Brons
  has served on the Supervisory Boards for Akzo Nobel Netherlands and IBM
  Netherlands, as well as the Advisory Board for Barcelona-based Almirall
  Prodesfarma. A citizen of the Netherlands, Mr. Brons was honored in 1996 by Her
  Majesty the Queen with the decoration of Knight of the Order of Lion of the
  Kingdom of the Netherlands, the country's highest civilian order. This honor was
  conferred for his meritorious achievements for Akzo Nobel and for his many
  international activities.
  
      "I am delighted to join a Board that includes so many distinguished
  directors," said Mr. Brons. "Before accepting this nomination, I had the
  opportunity to meet extensively with the senior leadership of Henry Schein and
  was impressed by the company's commitment to the highest standards of corporate
  conduct and the Team Schein culture that drives the organization. I hope to
  contribute to the continuation of Henry Schein's impressive growth for many
  years to come."
  
  ABOUT HENRY SCHEIN, INC.
  
      Henry Schein, a Fortune 500(R) company, is recognized for its excellent
  customer service and highly competitive prices. The Company's four business
  groups - Dental, Medical, International and Technology - serve more than 475,000
  customers worldwide, including dental practices and laboratories, physician
  practices and veterinary clinics, as well as government and other institutions.
  The Company's sales reached a record $4.1 billion in 2004. The Company operates
  through a centralized and automated distribution network, which provides
  customers in more than 125 countries with a comprehensive selection of over
  160,000 national and Henry Schein private-brand products.
  
      Henry Schein also offers a wide range of innovative value-added practice
  solutions, including such leading practice management software systems as
  DENTRIX(R) and Easy Dental(R) for dental practices, and AVlmark(R) for
  veterinary clinics, which are installed in over 50,000 practices; and ArubA(R),
  Henry Schein's electronic catalog and ordering system.
  
      Headquartered in Melville, N.Y., Henry Schein employs more than 10,000
  people in 19 countries. For more information, visit the Henry Schein Web site at
  www.henryschein.com.
                                        ###
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8khenryschein.txt", "secsgml_size_bytes": 9592}]
metadata_filer: {"company-data": {"conformed-name": "SCHEIN HENRY INC", "cik": "0001000228", "assigned-sic": "5047", "irs-number": "113136595", "state-of-incorporation": "DE", "fiscal-year-end": "1226"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27078", "film-number": "05743898"}, "business-address": {"street1": "135 DURYEA RD", "city": "MELVILLE", "state": "NY", "zip": "11747", "phone": "6318425500X6867"}, "mail-address": {"street1": "135 DURYEA RD", "city": "MELVILLE", "state": "NY", "zip": "11747"}}
text: UNITED STATES
                         SECURITIES AND EXCHANGE COMMISSION
                               WASHINGTON, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
           Date of Report (Date of earliest event reported): April 8, 2005
  
                                 HENRY SCHEIN, INC.
               (Exact name of registrant as specified in its charter)
  
          Delaware                     0-27078                 11-3136595
  --------------------------------------------------------------------------------
  (State or other jurisdiction of (Commission Number) (IRS Employer Identification
         incorporation)                                           No.)
  
                 135 Duryea Road Melville, New York                  11747
  --------------------------------------------------------------------------------
              (Address of principal executive offices)             (Zip Code)
  
  Registrant's telephone number, including area code:  (631) 843-5500
                                                     -----------------------------
  
  --------------------------------------------------------------------------------
           (Former name or former address, if changed since last report.)
  
  Check the appropriate box below if the Form 8-K filing is intended to
  simultaneously satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
  [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)
  
  [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)
  
  [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
      Act (17 CFR 240.14d-2(b))
  
  [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
      Act (17 CFR 240.13e-4(c))
  ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
  APPOINTMENT OF PRINCIPAL OFFICERS
  
  On April 8, 2005, the Company's Board of Directors authorized an increase in the
  number of directors, which constitute the entire Board of Directors, from
  fourteen to fifteen and appointed Paul Brons as a new director, effective
  immediately, to fill the vacancy created. Mr. Brons' term will expire at the
  Company's annual meeting of stockholders to be held on May 24, 2005. Attached
  hereto and incorporated herein by reference as Exhibit 99.1 is a copy of the
  Company's press release announcing Mr. Brons' appointment to the Company's Board
  of Directors.
  
  ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
  
  (c) Exhibit 99.1 - Press Release dated April 11, 2005.
  SIGNATURES
  
  Pursuant to the requirements of the Securities and Exchange Act of 1934, the
  Registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                            HENRY SCHEIN, INC.
  
  Date: April 11, 2005                       By:  /s/ Michael S. Ettinger
                                                ------------------------------
                                                Name: Michael S. Ettinger
                                                Title: Vice President and General
                                                       Counsel
  EXHIBIT 99.1
  
                           [LOGO OMITTED] HENRY SCHEIN(R)
                                N E W S R E L E A S E
           Henry Schein, Inc. - 135 Duryea Road, Melville, New York 11747
                                          FOR:     HENRY SCHEIN, INC.
                                          CONTACT: STEVEN PALADINO
                                                   EXECUTIVE VICE PRESIDENT &
                                                   CHIEF FINANCIAL OFFICER
                                                   (631) 843-5500
                                                   STEVEN.PALADINO@HENRYSCHEIN.COM
  
                                                   SUSAN VASSALLO
                                                   DIRECTOR,
                                                   CORPORATE COMMUNICATIONS
                                                   (631) 843-5562
                                                   SUSAN.VASSALLO@HENRYSCHEIN.COM
  
               HENRY SCHEIN APPOINTS PAUL BRONS TO BOARD OF DIRECTORS
  
               FORMER MEMBER OF AKZO NOBEL BOARD OF MANAGEMENT BRINGS
                     INTERNATIONAL AND PHARMACEUTICAL EXPERIENCE
  
  MELVILLE, N.Y., APRIL 11, 2005 - Henry Schein, Inc. (NASDAQ: HSIC), the largest
  distributor of healthcare products and services to office-based practitioners in
  the combined North American and European markets, today announced the
  appointment of Paul Brons to the Henry Schein Board of Directors. Mr. Brons is a
  former member of the Board of Management of Akzo Nobel NV, a leading
  manufacturer of diversified pharmaceutical, coatings and chemical products in
  over 75 countries.
  
      As a member of the Akzo Nobel Board of Management for eight years, Mr. Brons
  led all of the company's pharmaceutical business units, including human and
  veterinary pharmaceuticals, OTCs, generics, diagnostics and pharmaceutical
  active ingredients. In addition to his pharma responsibilities, Mr. Brons also
  supervised Akzo Nobel's corporate purchasing, information technology and
  international business development; as well as the company's activities in China
  and Latin America. Prior to his tenure on the Board of Management, Mr. Brons
  served as President of Organon International BV, one of Akzo Nobel's pharma
  business units, for nine years, the culmination of a 29-year career with that
  company, which included several posts abroad.
  
      "We are delighted to have a person of Paul's caliber join the Henry Schein
  Board of Directors," said Stanley M. Bergman, Chairman, Chief Executive Officer
  and President of Henry Schein. "Paul's wide-ranging international business
  experience and his expertise in pharmaceuticals have earned him a well-deserved
  reputation as one of Europe's premier pharmaceutical industry leaders. Our Board
  of Directors and management team look forward to the valuable contributions Paul
  will make to our company as we continue to expand internationally and add to our
  portfolio of pharmaceuticals, vaccines and other injectables."
  
                                      - more -
  Page 2
  
      While at Akzo Nobel, Mr. Brons contributed to the strengthening of the
  European Federation of Pharmaceutical Industry Associations (EFPIA), first as a
  member of its Strategic Advisory Committee, then as a member of their Board, and
  Chairman of EFPIA's EU Enlargement Committee. He was for many years actively
  involved in a worldwide policy group of CEOs from international R&D-based
  pharmaceutical companies, which sought to foster cooperation with governmental
  and non-governmental organizations. He also served as the European
  representative for the pharmaceutical industry at the Trans-Atlantic Business
  Dialogue, examining such issues as patent extension and AIDS in Africa.
  
      Since retiring from the Akzo Nobel Board of Management in 2002, Mr. Brons
  has served on the Supervisory Boards for Akzo Nobel Netherlands and IBM
  Netherlands, as well as the Advisory Board for Barcelona-based Almirall
  Prodesfarma. A citizen of the Netherlands, Mr. Brons was honored in 1996 by Her
  Majesty the Queen with the decoration of Knight of the Order of Lion of the
  Kingdom of the Netherlands, the country's highest civilian order. This honor was
  conferred for his meritorious achievements for Akzo Nobel and for his many
  international activities.
  
      "I am delighted to join a Board that includes so many distinguished
  directors," said Mr. Brons. "Before accepting this nomination, I had the
  opportunity to meet extensively with the senior leadership of Henry Schein and
  was impressed by the company's commitment to the highest standards of corporate
  conduct and the Team Schein culture that drives the organization. I hope to
  contribute to the continuation of Henry Schein's impressive growth for many
  years to come."
  
  ABOUT HENRY SCHEIN, INC.
  
      Henry Schein, a Fortune 500(R) company, is recognized for its excellent
  customer service and highly competitive prices. The Company's four business
  groups - Dental, Medical, International and Technology - serve more than 475,000
  customers worldwide, including dental practices and laboratories, physician
  practices and veterinary clinics, as well as government and other institutions.
  The Company's sales reached a record $4.1 billion in 2004. The Company operates
  through a centralized and automated distribution network, which provides
  customers in more than 125 countries with a comprehensive selection of over
  160,000 national and Henry Schein private-brand products.
  
      Henry Schein also offers a wide range of innovative value-added practice
  solutions, including such leading practice management software systems as
  DENTRIX(R) and Easy Dental(R) for dental practices, and AVlmark(R) for
  veterinary clinics, which are installed in over 50,000 practices; and ArubA(R),
  Henry Schein's electronic catalog and ordering system.
  
      Headquartered in Melville, N.Y., Henry Schein employs more than 10,000
  people in 19 countries. For more information, visit the Henry Schein Web site at
  www.henryschein.com.
                                        ###